Dr. Hong Li and her lab (IMAGE)

Van Andel Research Institute

Dr. Hong Li and her lab — Caption

A team led by Van Andel Institute's Dr. Hong Li and Wageningen University & Research's Dr. John van der Oost has used a CRISPR variant called ThermoCas9 to distinguish tumor DNA from healthy DNA and selectively cut only the former. The findings are a promising step toward possible future high-precision cancer therapies. Dr. Li (second from right) is pictured above with members of her lab who are co-first authors of the study, published April 15 in Nature.

Credit

Courtesy of Van Andel Institute

Usage Restrictions

Please include attribution

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.